Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edesa Biotech Inc (NQ: EDSA )

3.200 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edesa Biotech Inc

< Previous 1 2 3 4 5 Next >
Why Edesa Biotech Shares Are Trading Higher Today
Edesa Biotech Inc (NASDAQ: EDSA) is trading higher Tuesday after the company announced additional results from the Phase 2 part of the ongoing Phase 2/3 study of EB05 in... 
Via Benzinga
Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study
- Mortality reductions demonstrated across multiple patient groups - Additional efficacy signals recorded in a broad range of mild to severe ARDS patients - Company to focus on critically ill... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
50 Biggest Movers From Yesterday
Check out these big penny stock gainers and losers Losers Edesa Biotech, Inc. (NASDAQ: EDSA) shares dipped 29.9% to close at $8.36 on profit-taking after the stock... 
Via Benzinga
Mid-Afternoon Market Update: Dow Edges Lower; Helbiz Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 0.11% to 33,932.34 while the NASDAQ rose 0.18% to 14,740.41. The S&P also fell, dropping 0.09% to 4,353.81. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
How To Play Edsa Biotech's Stock After 60% Surge
Edsa Biotech Inc. (NASDAQ:EDSA) shares are trading higher ... 
Via Benzinga
Mid-Day Market Update: Gold Rises 1%; Verrica Pharmaceuticals Shares Slide
Midway through trading Tuesday, the Dow traded up 0.44% to 34,119.86 while the NASDAQ rose 0.66% to 14,810.89. The S&P also rose, gaining 0.43% to 4,376.48. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
32 Stocks Moving In Tuesday's Mid-Day Session
Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 177.4% to $39.83. Helbiz Media, the media arm of Helbiz announced a deal with Amazon Italy, a unit of Amazon.com. ReWalk... 
Via Benzinga
Mid-Morning Market Update: Markets Gain; AutoZone Earnings Beat Views
Following the market opening Tuesday, the Dow traded up 0.14% to 34,017.77 while the NASDAQ rose 0.39% to 14,771.47. The S&P also rose, gaining 0.18% to 4,365.67. The U.S. has... 
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
Exposures COVID-19
18 Stocks Moving in Tuesday's Pre-Market Session
Gainers ReWalk Robotics Ltd. (NASDAQ: RWLK) rose 37% to $1.78 in pre-market trading after declining around 4% on Monday. ReWalk Robotics, last month, reported Q2 sales of $1.44... 
Via Benzinga
48 Biggest Movers From Yesterday
Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 data of its monoclonal antibody in hospitalized... 
Via Benzinga
EDSA Stock: The Covid-19 News Sending Edesa Biotech Soaring on Monday
Today, the announcement of positive clinical trial results has sent investors in Edesa Biotech and EDSA stock on a nice ride. 
Via InvestorPlace
Exposures COVID-19
Why Edesa Biotech Shares Are Soaring Today
Edesa Biotech Inc (NASDAQ: EDSA) is surging higher Monday after the company announced positive Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients... 
Via Benzinga
Exposures COVID-19
Mid-Afternoon Market Update: Dow Tumbles 2.5%; BeyondSpring Shares Plunge
Toward the end of trading Monday, the Dow traded down 2.57% to 33,696.98 while the NASDAQ fell 3.14% to 14,572.25. The S&P also fell, dropping 2.58% to 4,318.67. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Edesa Biotech Stock Is Rallying After COVID-19 Antibody Data: What You Need To Know
Edesa Biotech Inc (NASDAQ: EDSA) has announced positive results from the Phase 2 part of an ongoing Phase 2/3 study evaluating EB05 as a single-dose treatment for... 
Via Benzinga
Exposures COVID-19
Mid-Day Market Update: Crude Oil Down 2%; Synlogic Shares Spike Higher
Midway through trading Monday, the Dow traded down 1.51% to 34,063.71 while the NASDAQ fell 2.13% to 14,723.20. The S&P also fell, dropping 1.64% to 4,360.41. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
35 Stocks Moving In Monday's Mid-Day Session
Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday. Edesa Biotech, Inc. (NASDAQ: EDSA) jumped 30.6% to $7.68 after the company... 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; Brooks Automation Divests Semiconductor Business For $3B
Following the market opening Monday, the Dow traded down 1.42% to 34,093.46 while the NASDAQ fell 1.86% to 14,763.93. The S&P also fell, dropping 1.54% to 4,364.65. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients
- Study unblinded due to strong efficacy signal for 28-day mortality endpoint - Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over Standard of Care... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Edesa Biotech to Present at the H.C. Wainwright Global Investment Conference
TORONTO, ON / ACCESSWIRE / September 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Edesa Biotech Provides Update For COVID-19 Antibody Trial
Edesa Biotech Inc (NASDAQ: EDSA) issued an update for the Phase 2/3 study evaluating its monoclonal antibody candidate, EB05, as single-dose therapy for... 
Via Benzinga
Exposures COVID-19
Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule
- Delta variant contributes to rapid enrollment amid growing scientific rationale for targeting Toll-like Receptor 4 (TLR4) Blinded interim analysis from Phase 2/3 study expected in current quarter... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results
TORONTO, ON / ACCESSWIRE / August 13, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Edesa Biotech Extends Dermatitis Study to Canada
TORONTO, ON / ACCESSWIRE / July 13, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Edesa Biotech Team Expands Leadership Team with Key Manufacturing Appointment
TORONTO, ON / ACCESSWIRE / June 23, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Edesa Biotech Reports Favorable Review of COVID-19 Study
TORONTO, ON / ACCESSWIRE / June 18, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that an... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Edesa Biotech to Attend BIO Digital 2021
TORONTO, ON / ACCESSWIRE / June 8, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Edesa Biotech's EB01 Shows Encouraging Interim Results In Dermatitis Trial
Edesa Biotech Inc's (NASDAQ: EDSA) EB01 has met a key interim study parameter as part of an adaptive Phase 2b trial evaluating EB01 as monotherapy... 
Via Benzinga
Edesa Biotech Reports Positive Interim Results in Dermatitis Trial
TORONTO, ON / ACCESSWIRE / June 3, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Edesa Biotech to Join Panel Discussion at Industry Event
TORONTO, ON / ACCESSWIRE / May 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.